BDBiping Deng

Biping Deng

*This is an algorithmically generated author record based on publicly available information.

Biping Deng has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: single-arm, open-label, phase I study

    by Kai Hu, Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Alex H. Chang, Haifeng Wu, et al.

    CD7-directed chimeric antigen receptor (CAR)-T cell therapy has shown early efficacy in patients with refractory or relapsed T cell acute lymphoblastic leukemia (r/r T-ALL). However, manufacturing difficulties remain key challenges. We conducted a phase I study (ChiCTR2200058969) with 3 + 3 low dose-escalation followed by cohort expansion was designed in r/r T-cell lymphoma patients. CD7 CAR-T cells were isolated from patients or from previous stem-cell transplantation donors. The phase Ia study is being conducted with the following dose levels (DL): 1×10 4 , 5×10 4 , and 1×10 5 (± 30%) CAR-T cells/kg. Of 40 patients enrolled, 31 received the recommended phase Ib dose of 1×10 5 (± 30%) CAR-T cells/kg.The most common treatment-related adverse event (AE) within 30 days included cytokine release syndrome (CRS) (92.5%;5% grade 3–4), neutropenia (100%; 97.5% grade 3–4), thrombocytopenia (100%; 85% grade 3–4).In the Ib phase (n = 31), the ORR was 93.5% (29/31) and the CR rate was 80.6% (25/31). For responders in phase Ib (n = 29), patients who received allo-HSCT consolidation (n = 16) had superior 2-year OS compared to patients without allo-HSCT consolidation (n = 13) [54.1% (95% CI: 26.7–75.2) vs. 23.1% (95% CI:5.6–47.5) (P = 0.038)].low-dose CD7 CAR-T cell therapy is effective against r/r T-NHL, and allo-HSCT after achieving remission with CD7 CAR-T therapy can significantly prolong survival.

  • Open Access

    Metabotropic glutamate receptor 4-mediated glutamatergic signaling reshapes the tumor microenvironment by regulating dendritic cell maturation

    by Xiaoman Ju, Eva Maria Putz, Yaqi Liu, Dongchen Yuan, Guowei Sun, Stephane Koda, Zhuo Fu, Simin Shao, Chunrong Tong, Biping Deng, et al.

    Metabotropic glutamate receptor 4 (mGluR4, encoded by Grm4), is a neurotransmitter receptor, known to play roles in tumor progression and immune modulation through the nervous system. Here we show that mGluR4 may regulate immune responses in the tumor microenvironment (TME) also via non-neuronal mechanisms. We observe that dendritic cells (DC) from mGluR4-deficient mice display enhanced migration, maturation and antigen-presentation capacity, which promote T cell and NK cell responses against tumor cells. Tumor growth and metastases are suppressed in Grm4-/- mice in different preclinical tumor models, including orthotopic liver cancer, subcutaneous melanoma, colorectal tumors, and fibrosarcoma. We show that the tumor suppressive effect of Grm4-deficiency requires host immunity, in particular CD8+ T cells, NK cells, and IFNγ, but independent of the nervous system. Single-cell RNA-sequencing and ex vivo assays show changes in the composition and functional state of the immune TME. Mechanistically, mGluR4 suppresses the adenyl cyclase/PKA signaling pathway, leading to metabolic reprogramming of DCs. Importantly, adoptive transfer of DCs pretreated with the AC agonist forskolin therapeutically suppressed tumor growth in an orthotopic liver cancer model. Our study thus demonstrates that mGluR4 is a checkpoint for DC maturation and that mGluR4 may serve as an immunotherapeutic target.


  • Top Cited Papers

    Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial

    by Jing Pan, Yue Tan, Lingling Shan, Samuel Seery, Biping Deng, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, et al.

    Refractory or relapsed T cell acute lymphoblastic leukemia (r/r T-ALL) patients have poor prognoses, due to the lack of effective salvage therapies. Recently, CD7-targeting chimeric antigen receptor (CAR)-T therapies show efficacy in patients with r/r T-ALL, but relapse with CD7 loss is common. This study evaluates a CD5-gene-edited CAR-T cell therapy targeting CD5 in 19 r/r T-ALL patients, most of whom had previously failed CD7 CAR-T interventions. CAR-T products were derived from previous transplant donors (Cohort A) or newly matched donors (Cohort B). Primary endpoints were dose-limiting toxicity at 21 days and adverse events within 30 days. Secondary endpoints were responses, pharmacokinetics and severe adverse events after 30 days. A total of 16 received infusions, 10 at target dose of 1 × 106 kg−1. All encountered grade 3–4 cytopenias and one had a grade 3 infection within 30 days. All patients (100%) achieved complete remission or complete remission with incomplete blood count recovery by day 30. At a median follow-up of 14.3 months, four received transplantation; three were in remission and one died of infection. Of 12 untransplanted patients, 2 were in remission, 3 relapsed, 5 died of infection and 2 of thrombotic microangiopathy. CAR-T cells persisted and cleared CD5+ T cells. CD5− T cells, mostly CD5-gene-edited, increased but remained below normal levels. These results suggest this CD5-specific CAR-T intervention has a high remission rate for T-ALL patients. Evidence also suggests the risk of late-onset severe infection may be mitigated with consolidative transplantation. This study provides insights that could help to optimize this promising intervention. ClinicalTrials.gov registration: NCT05032599.


  • Open Access

    T-cell engineering strategies for tumors with low antigen density, and T-cell survival in the immunosuppressive tumor microenvironment of relapsed/refractory diffuse large B-cell lymphoma

    by Rong Sheng Luan, Biping Deng

    Refractory and/or relapsed (r/r) diffuse large B-cell lymphomas after treatment with two lines of systemic chemoimmunotherapy exhibit diversity in genetics, tissue biology, and pathology, as well as poor prognosis. Patient TCRαβ cells engineered with a CD19-specific chimeric antigen receptor (CAR) have shown promising clinical outcomes in r/r diffuse large B-cell lymphoma. The ZUMA-1 study, the JULIET study, and the TRANSCEND NHL 001 study of three prototype 19CAR-T cells have indicated an overall response rate of 52–82%, a complete response rate of 40–58%, and a 12-month progression-free survival of 33.2%–46.6%, with clinically manageable treatment related toxicity. At the 5-year follow-up, relapse was observed in approximately 57% of patients within 1 year. Understanding of the risk factors for non-response remains insufficient. In addition to intrinsic tumor resistance, such as aberrant apoptotic signaling, downregulation or loss of tumor-associated antigens (TAA), an immunosuppressive tumor microenvironment, and CAR-T cell exhaustion in vivo have been suggested to be important risk factors. Mechanisms underlying 19CAR-T cell exhaustion under chronic TAA exposure, and limited 19CAR-T cell trafficking and infiltration into the tumor mass have been reported. Moreover, tumor escape in the presence of low TAA density remains a challenge in 1928ζ CAR-T cell treatment. In this review, we provide an overview of modified modular CAR elements and their synergistic effects in controlling T-cell function. We then briefly discuss novel strategies against tumors with low TAA density, such as bispecific tandem or loop CAR recognition domains, the development of human leukocyte antigen-independent synthetic TCRαβ double-chain receptors integrated into the constant region of the TCRα chain, and armored CAR-T cells targeting the tumor microenvironment.

  • Open Access

    Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL

    by Biping Deng, Jing Pan, Zhaoli Liu, Shuangyou Liu, Yunlong Chen, Xiaomin Qu, Yu'E Zhang, Yuehui Lin, Yanlei Zhang, Xinjian Yu, et al.